09.00 – 10.00 |
Wolfson
Theatre |
|
|
Plenary
Lecture 3: |
|
|
Society
for Endocrinology Medal Lecture |
|
|
Chair: Bloom
S (London) |
| |
|
|
S3 |
09.00 |
The
placenta’s endocrine dilemma: scavenging
the mother whilst sparing the
foetus |
|
|
Lowry
PJ (Reading) |
|
|
|
10.00 – 10.30 |
Osler
Room |
|
|
Coffee |
|
|
|
10.30 – 12.30 |
Sloane
Room |
|
|
Oral
Communication 3: |
|
|
Growth
and Development |
|
|
Chair: Ross
R (Sheffield) & Hill D(Ontario,Canada) |
| |
|
|
OC15 |
10.30 |
*Spontaneous
differentiation of mouse
embryonic stem cells into an
islet phenotype |
|
|
Milne
HM, Burns CJ, Minger S, Persaud SJ & Jones
PM |
|
|
|
OC16 |
10.45 |
Overexpression
of insulin-like growth factor
binding protein-5 (IGFBP5) in mice
results in compromised muscle development |
|
|
Salih
DAM, Holding C, Tripathi G, Cobb LJ, Gonzalez
I, Carter EJ, Lovett FA & Pell JM |
|
|
|
OC17 |
11.00 |
Bone
morphogenetic protein-2-receptor
expression and function in
pituitary gonadotrophs |
|
|
Sidhu KK, Stoddart HL & Burrin JM |
|
|
|
OC18 |
11.15 |
Testosterone
17beta-hydroxysteroid dehydrogenase
activities of mouse type I and
VI 3beta-hydroxysteroid dehydrogenases |
|
|
Howe BEC, Howie AF, Morley SD, Payne AH & Mason JI |
|
|
|
OC19 |
11.30 |
Differential
effects of maternal nutrition on
molecular indices of fetal adipose tissue
development and function |
|
|
Bispham J, Stephenson T & Symonds ME |
|
|
|
OC20 |
11.45 |
The
effect of maternal nutrition during the
first or second half of gestation on glucose
tolerance of the sow |
|
|
Corson
AM, Litten JC, Perkins KS, Laws J & Clarke
L |
|
|
|
OC21 |
12.00 |
Chronic
umbilical cord compression blunts
the fetal plasma arginine vasopressin
(AVP) response to subsequent
acute hypoxaemia |
|
|
Gardner DS, Fowden AL & Giussani DA |
|
|
|
OC22 |
12.15 |
Reassessment
of growth hormone status is
required at final height in children treated
with growth hormone replacement
following radiation |
|
|
Gleeson
HK, Gattamaneni HR, Smethurst L, Brennan
BM & Shalet SM |
|
|
|
10.30 – 12.30 |
Wolfson
Theatre |
|
|
Symposium
3: |
|
|
Melanocortin
receptors |
|
|
Chair: Farooqi
S (Cambridge) |
| |
|
|
S13 |
10.30 |
Role
of brainstem melanocortin system
in CCK-mediated satiety |
|
|
Fan
W, Ellacott KLJ, Halatchev I, Takahashi K & Cone RD (Portland,USA) |
|
|
|
S14 |
11.00 |
Brain
melanocortin receptors - feeding
and energy expenditure |
|
|
Small C (London) |
|
|
|
S15 |
11.30 |
N-terminal
POMC ligands and
their receptors |
|
|
Bicknell AB (Reading) |
|
|
|
S16 |
12.00 |
Melanocortin
receptors in the
anterior pituitary |
|
|
Denef
C (Gastuisberg,Belgium) & Langouche L |
|
|
|
12.30 – 13.00 |
Osler
Room |
|
|
Lunch |
|
|
|
13.00 – 14.30 |
Library |
|
|
Attended
Posters |
|
|
|
13.30 – 14.30 |
Wolfson
Theatre |
|
|
Clinical
Endocrine Debate: |
|
|
This
house believes that the investigation of
thyroid nodules should be simplified to a
syringe and needle |
|
|
Chair: Vanderpump
M (London) |
| |
|
|
S17 |
|
Proposer:
Franklyn J(Birmingham) |
| |
|
|
S18 |
|
Opposer:
Lazarus J (Cardiff) |
|
|
|
14.30 – 16.30 |
Sloane
Room |
|
|
Oral
Communication 4: |
|
|
Neuroendocrinology |
|
|
Chair: Bloom
S (London) & Buckingham J (London) |
|
|
|
OC27 |
14.30 |
*The
MC3-R does not play a role in mediating
the effects of gamma-MSH peptides
on the adrenal |
|
|
Harmer
SC & Bicknell AB |
| |
|
|
OC24 |
14.45 |
*PACAP
stimulates phosphorylation and ligand-binding
activity of steroidogenic factor-1
in alphaT3-1 gonadotrophs |
|
|
Fowkes
RC, Desclozeaux M, Ingraham HA & Burrin JM |
|
|
|
OC25 |
15.00 |
Sexual
dimorphism in anterior pituitary function
in the annexin 1 knockout mouse |
|
|
John
CD, Morris JF, Christian HC, Flower RJ & Buckingham JC |
|
|
|
OC26 |
15.15 |
Suppression
of the hypothalamo-pituitary adrenal
axis by long-term intra-arcuate cocaine-
and amphetamine-regulated transcript
(CART) |
|
|
Stanley
SA, Kong WM, Abbott CR, Gardiner JV, Ghatei
MA, Small CJ & Bloom SR |
|
|
|
OC23 |
15.30 |
Receptor
shedding:A novel mechanism for
the disinhibition of CNS neuronal growth |
|
|
Ahmed Z, Dent RG, Berry M & Logan A |
|
|
|
OC28 |
15.45 |
Safety
and efficacy of converting patients with
acromegaly from long-acting octreotide
to pegvisomant |
|
|
Drake
WM, Rowles SV, Paisley AN, Stewart
PM, Monson JP & Trainer P |
|
|
|
OC29 |
16.00 |
Efficacy
and safety of titrated-doses lanreotide
autogel in patients with acromegaly |
|
|
Jenkins
PJ, on behalf of the Lanreotide Autogel Study
Group |
|
|
|
OC30 |
16.15 |
Circulating
cocaine- and amphetamine-regulated
transcript (CART) peptide in subjects
with abnormalities of the hypothalamo-pituitary
axis |
|
|
McDermott
FD, Stanley SA, Murphy KG, Ghatei
MA & Bloom SR |
|
|
|
| 14.30 – 16.30 |
Wolfson Theatre |
| |
|
Symposium 4:
The endocrinologist and bone |
| |
|
Chair: Selby P (Manchester) |
| |
|
|
S19 |
14.30 |
Osteoporosis in inflammatory bowel disease |
| |
|
Compston J (Cambridge) |
| |
|
|
S20 |
15.00 |
11beta-hydroxysteroid dehydrogenase type 1: a pre-receptor regulator of
glucocroticoids in bone |
| |
|
Hewison M (Birmingham) |
| |
|
|
S21 |
15.30 |
PTH in the treatment of osteoporosis: the dawn of the anabolic era |
| |
|
Russell RG (Oxford) |
| |
|
|
S22 |
16.00 |
Statins and bone |
| |
|
Eastell R (Sheffield) |
| |
|
|
| 16.30 – 16.45 |
Osler Room |
| |
|
Tea & Prizes |